Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
175
resultados
Última actualización
03/05/2025 [06:53:00]
Resultados 50 a 75 de 175
Resumen de: WO2025090612A1
The present technology provides a compound of Formula I, wherein PAO, R and n are defined herein. Also provided are lipid nanoparticles incorporating compounds of Formula I and methods of using same to deliver nucleotide, polynucleic acid or RNP to a cell.
Resumen de: WO2025090968A1
Bead-in-particles formats and their use in cytometric applications are described. In one aspect, the disclosure provides a bead-in-particle comprising an outer hydrogel body and an inner hydrogel bead. As described herein, the bead-in-particle is selectively tuned to have at least one morphological property substantially similar to subcellular macrostructures of interest present in a target cell. In one aspect of the disclosure, the bead-in-particle are used as a calibration reagent for the detection of a target cell in a sample, such as by image-based flow cytometry.
Resumen de: WO2025090525A1
The disclosure provides conjugates comprising a targeting moiety a lipid nanoparticle (LNP) encapsulating a therapeutic agent (e.g., payload) for delivery to immune cells. The conjugates can be delivered to immune cells ex vivo or formulated in a pharmaceutical composition and can be directly administered to a subject in need of (i.e., via in vivo administration).
Resumen de: WO2025090891A1
In some embodiments, the invention relates to a composition for targeted delivery of intact mitochondrial DNA (mtDNA) to a target cell, the composition comprising a mtDNA molecule that is complexed to cell-penetrating peptides (CPPs) which promote cellular entry, wherein the complex forms a nanoparticle with the CPPs bound to the mtDNA molecule. In some embodiments, the invention relates to a method of treating a disease or disorder associated with mitochondrial dysfunction in a subject in need thereof.
Resumen de: WO2025090766A1
This invention relates to the utilization of superpararmagnetic polycrystalline iron oxide nanoparticles for magnetic hperthermia applications and methods. The present invention provides a magnetic hyperthermia method for treating a condition in a subject, the method comprising: obtaining at least one superparamagnetic nanoparticle, wherein the at least one superparamagnetic nanoparticle comprises a plurality of iron oxide primary crystals, wherein the plurality of iron oxide primary crystals comprise a plurality of crystallites.
Resumen de: WO2025090634A1
Compositions comprising a mesoporous silica nanoparticle (MSN) loaded with metal cations and oligonucleotides and methods of use.
Resumen de: WO2025090565A1
Methods and compositions for rejuvenating and reprogramming stem cells are disclosed. The methods involve administering to a subject an ABCB5 targeted composition comprising an anti-ABCB5 antibody conjugated to a therapeutic payload comprised of an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor in an effective amount to reprogram and rejuvenate ABCB5+ stem cells in the subject. The compositions include anti-ABCB5 antibody conjugated to a therapeutic payload comprising an epigenetic reprogramming factor or a nucleic acid encoding an epigenetic reprogramming factor.
Resumen de: WO2025090422A1
The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., immune effector cells such as T cells, B cells, natural killer cells, and dendritic cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Resumen de: WO2025090138A1
The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, hematopoietic stem cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.
Resumen de: WO2025089792A1
The present invention relates to a composition for drug delivery and a preparation method therefor and, more specifically, to: a composition for drug delivery which is formed such that a drug is encapsulated inside a nanoparticle structure formed by a polymer and a cationic lipid having a specific structure; and a preparation method therefor.
Resumen de: WO2025089791A1
The present invention relates to a novel ionizable lipid compound represented by Formula (I) or a salt thereof, and a lipid nanoparticle containing the same. The lipid nanoparticle containing the novel ionizable lipid compound according to the present invention has an excellent nucleic acid encapsulation efficiency and has a high efficiency of cellular delivery of nucleic acid.
Resumen de: WO2025089790A1
The present invention relates to a novel ionizable lipid compound represented by formula (I), or a salt thereof, and lipid nanoparticles comprising same. The lipid nanoparticles comprising the novel ionizable lipid compound, according to the present invention, have excellent nucleic acid encapsulation efficiency and high nucleic acid cell delivery efficiency.
Resumen de: WO2025089475A1
The present invention relates to a nucleic acid-encapsulated stabilized nanoliposome carrier and a method for producing same.
Resumen de: WO2025088609A1
Disclosed are biocompatible, biodegradable, and low immunogenic alga(e) Nanoparticles (aNPs) that can adhere and deliver active ingredient(s) to mucosal epithelium tissue, as well as compositions comprising the aNPs, methods of preparing the aNPs, and uses thereof in methods of treatment.
Resumen de: WO2025088597A1
A method is provided for treating solid tumors in a human body, the method including intravenously administering nanoparticles (32) having a negative zeta potential (ZP) at neutral pH between -5 and -40 mV; and administering chemotherapy drug molecules (34) having a positive ZP at neutral pH or a ZP at neutral pH of between -10 mV and 0 mV. The nanoparticles (32) and the chemotherapy drug molecules (34) are separate from each other until in the human body. The nanoparticles (32) and the chemotherapy drug molecules (34) are administered in respective amounts that are therapeutically effective in combination. The nanoparticles (32) localize on cancer cells of the tumors. The chemotherapy drug molecules (34) are attracted to the nanoparticles (32) in the human body by the opposite charges of the chemotherapy drug molecules (34) and the nanoparticles (32), thereby facilitating localization of the chemotherapy drug molecules (34) on the cancer cells of the tumors. Other embodiments are also described.
Resumen de: WO2025088242A1
A first aspect of the present invention relates to a nanoparticle aggregate for the treatment of venous thrombosis characterised in that it comprises a combination of negatively charged nanoparticles comprising rtPA and positively charged nanoparticles comprising DNase per nanoparticle. A second aspect of the present invention relates to a method for producing the nanoparticle aggregate. A third aspect of the invention relates to a pharmaceutical composition comprising the nanoparticle aggregate according to the first aspect of the invention. Lastly, the present invention discloses the nanoparticle aggregate for use as a drug and for the treatment of thromboembolic diseases.
Resumen de: WO2025087303A1
A nanoparticle complex comprises a bifunctional binder capable of non-covalently binding to the lipid nanoparticle in the nanoparticle complex.
Resumen de: WO2025086482A1
Disclosed in the present invention is an ionizable lipid compound and a use thereof. The ionizable lipid compound has a structure as represented by formula (I). In the ionizable lipid compound of the present invention, a polyoxa-structure is introduced in combination with a hydroxyl group at the head, so that the lipid compound has good biocompatibility and excellent in vivo mRNA delivery efficiency. The structural design is novel, the proportion of each component of a matched LNP dosage form is appropriate, and animal experiments have demonstrated that the delivery effect reaches an international advanced level of commercialized ionizable lipids and the safety is good.
Resumen de: WO2025086003A1
A Janus particle, comprising a particle core, the particle core comprising at least a first surface functionalized with a functional group and a second surface functionalized with a metal particle.
Resumen de: WO2025088346A1
Provided is lipid nanoparticle functionalised with a glycopolymer. The glycopolymer comprises at least four carbohydrate units, wherein each carbohydrate unit is independently selected from a monosaccharide, a disaccharide and an oligosaccharide. The lipid nanoparticle can be used for inducing an immune response in a subject.
Resumen de: AU2022463987A1
The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.
Resumen de: WO2023247047A1
The present invention refers to a peptide, comprising or consisting of SEQ ID NO: 1 (CAYMTMKIRN), for use as a medicament, preferably in the prevention and/or treatment of cardiac damage arising after ischemia followed by reperfusion, or in the prevention and/or treatment of the inflammatory response following acute myocardial infarction. In a preferred embodiment, the peptide is conjugated with a nanoparticle.
Resumen de: EP4545561A1
The present invention relates to a novel nanobody (Nb) and a nanobody-drug conjugate (NDC) targeting CD73, a method for preparing same, and use thereof. The monoclonal nanobody and the corresponding NDC can efficiently bind to isolated CD73, various tumor cells and CD73 on the surface of an immune cell with high specificity and block the catalytic activity of CD73 enzymes, exhibiting high affinity, low immunogenicity, and a significant anti-tumor effect.
Nº publicación: EP4543847A2 30/04/2025
Solicitante:
TURN BIOTECHNOLOGIES INC [US]
Turn Biotechnologies, Inc
Resumen de: AU2023288487A1
The disclosure relates to ionizable lipids and compositions comprising the ionizable lipids. Lipid-nanoparticle compositions comprised of an ionizable lipid, optionally in combination with other lipid components such as helper lipids, stabilization lipids and structural lipids, and a therapeutic agent, such as a nucleic acid, for delivery to mammalian cells or organs are described.
BOPI
Sede Electrónica
